The present application addresses the general problem of antibiotic resistance, in particular antibiotic-resistant tuberculosis (TB). The long-term goal of this research program is to develop new DNA gyrase inhibitors that are highly effective anti-tuberculosis (TB) agents with susceptible, multidrug-resistant, extensively drug- resistant, and completely drug-resistant forms of the disease. The specific goal of the present application is to develop a novel anti-mutant strategy for identifying lead antibacterial agents that will severely restrict the emergence of resistant mutants and to exploit the strategy to specifically identify anti-mutant gyrase inhibitors that are active against wild-type and quinolone-resistant mutants of M. tuberculosis. The anti-mutant strategy is based on the central hypothesis that new antibiotics having a closed or very narrow mutant selection window will severely restrict the rate at which resistant mutants emerge. Such antibiotics are expected to have increased clinical utility and longevity of use. Preliminary studies show that anti-mutant activity of new gyrase inhibitors does narrow the mutant selection window and restricts the recovery of induced mutants.
Three specific aims have been developed to integrate medicinal chemistry, microbiology, biochemistry and molecular modeling studies into a new anti-mutant strategy and to identify lead structures for development as effective anti-TB agents.
In Aims 1 and 2 we will develop new dione-class and C-7 aryl-quinolone-class agents that are active against wild-type cells, known quinolone-resistant gyrase mutants, and induced mutants generated against progenitor compounds within each class. In a third aim we will exploit two different models for agents binding to gyrase to identify and characterize new types of anti-mutant gyrase inhibitors. The expected outcome of this work is the generation of new lead gyrase inhibitors that exhibit a narrow mutant selection window and severely restrict the recovery of resistant mutants. Successful completion of these studies will provide a general framework for obtaining agents with excellent anti-mutant activity. The framework is expected to apply to many other structural and mechanistic antibiotic classes.
Antibiotic resistance has been recognized for more than a decade as a major threat to public health in the US and elsewhere;patients are now dying from once-treatable infections, and few new compounds are in the drug pipeline. Developing a new approach and new criteria for creating novel antibiotics that will restrict the emergence of resistant bacteria will lead to more effective, longer-lived compounds. Application of the ideas to tuberculosis will be significant because on a global basis tuberculosis kills more people than any other infectious disease and because drug-resistant tuberculosis is growing in prevalence.
|Hiasa, Hiroshi (2018) DNA Topoisomerases as Targets for Antibacterial Agents. Methods Mol Biol 1703:47-62|
|Oppegard, Lisa M; Delgado, Justine L; Kulkarni, Chaitanya A et al. (2018) Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity. Invest New Drugs :|
|Delgado, Justine L; Hsieh, Chao-Ming; Chan, Nei-Li et al. (2018) Topoisomerases as anticancer targets. Biochem J 475:373-398|
|Towle, Tyrell R; Kulkarni, Chaitanya A; Oppegard, Lisa M et al. (2018) Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase. Bioorg Med Chem Lett 28:1903-1910|
|Ashley, Rachel E; Lindsey Jr, R Hunter; McPherson, Sylvia A et al. (2017) Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance. Biochemistry 56:4191-4200|
|Blower, Tim R; Williamson, Benjamin H; Kerns, Robert J et al. (2016) Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 113:1706-13|
|Malik, Muhammad; Mustaev, Arkady; Schwanz, Heidi A et al. (2016) Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. Nucleic Acids Res 44:3304-16|
|Aldred, Katie J; Blower, Tim R; Kerns, Robert J et al. (2016) Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci U S A 113:E839-46|
|Oppegard, Lisa M; Schwanz, Heidi A; Towle, Tyrell R et al. (2016) Fluoroquinolones stimulate the DNA cleavage activity of topoisomerase IV by promoting the binding of Mg(2+) to the second metal binding site. Biochim Biophys Acta 1860:569-75|
|Liu, Yuanli; Zhou, Jinan; Qu, Yilin et al. (2016) Resveratrol Antagonizes Antimicrobial Lethality and Stimulates Recovery of Bacterial Mutants. PLoS One 11:e0153023|
Showing the most recent 10 out of 26 publications